NAFDAC Issues Warning Against Suspected Substandard Antibiotic ‘Deekins Amoxycillin 500mg Capsules’.
The National Agency for Food and Drug Administration and Control (NAFDAC) has issued a public warning against the use of Deekins Amoxycillin 500mg Capsules. The product, manufactured by Ecomed Pharma Ltd and marketed by Devine Kings Pharmaceutical Ltd, is currently under investigation following reports of serious adverse reactions.
In a statement signed by NAFDAC’s Director-General, Prof. Mojisola Christianah Adeyeye, the agency revealed it is focusing on lot number 4C639001 of the medication, which has been linked to multiple adverse reactions reported by patients nationwide.
“We are investigating reports of serious adverse drug reactions being experienced by patients who took the medication across the country,” said Prof. Adeyeye. She urged distributors, healthcare providers, and the public to exercise caution by avoiding the sale, distribution, and use of the affected lot.
The agency also reminded consumers to only purchase medical products from authorised suppliers and to verify their authenticity and condition. Those in possession of the affected batch have been directed to immediately cease its use and return any remaining stock to the nearest NAFDAC office.
Prof. Adeyeye added that an alert against the product had been issued on 3 December 2024, and she encouraged healthcare professionals and consumers to report suspected cases of substandard medicines to NAFDAC’s offices or through its e-reporting platform.
Further investigation has revealed discrepancies surrounding the production of the affected lot. According to Ecomed Pharma Ltd, the manufacturer, the batch in question (4C639001) comprised only 20 packets produced for registration renewal purposes. However, an alarming 790 packets, with a manufacturing date of March 2024 and an expiry date of February 2027, were recalled—products the manufacturer claims not to have produced.
Prof. Adeyeye stated that Quality Control and Production Managers have been invited for further investigation, and laboratory analyses of the suspected batch are underway.
Meanwhile, the Marketing Authorisation Holder (MAH), Devine Kings Pharmaceutical Ltd, confirmed in its statement that all products in circulation were manufactured by Ecomed Pharma Ltd.
The situation is being closely monitored, with NAFDAC reaffirming its commitment to ensuring public health safety. Consumers are advised to remain vigilant and report any adverse reactions or irregularities to NAFDAC through its available platforms.
